$CELZ
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. Stock $celz

$celz Overview Financials Valuation SEC Filings Company Website

2021 Form 10-K Financial Statement

#000147793222001741 Filed on March 30, 2022

Income Statement

Concept	2021	2020 Q4	2020
Revenue	$87.75K	$17.50K	$164.5K
YoY Change	-46.65%	-89.43%	-0.6%
Cost Of Revenue	$47.95K	$8.000K	$50.60K
YoY Change	-5.23%	-82.42%	11.2%
Gross Profit	$39.81K	$9.500K	$113.9K
YoY Change	-65.05%	-92.08%	-5.08%
Gross Profit Margin	45.36%	54.29%	69.24%
Selling, General & Admin	$2.964M	$315.8K	$1.162M
YoY Change	155.13%	-74.18%	-5.01%
% of Gross Profit	7447.53%	3324.11%	1020.11%
Research & Development	$109.2K		$0.00
YoY Change
% of Gross Profit	274.29%		0.0%
Depreciation & Amortization	$92.08K	$16.77K	$66.79K
YoY Change	37.86%	51.22%	147.83%
% of Gross Profit	231.33%	176.53%	58.64%
Operating Expenses	$3.166M	$332.6K	$1.229M
YoY Change	157.64%	-73.4%	-1.71%
Operating Profit	-$3.126M	-$323.1K	-$1.115M
YoY Change	180.4%	-71.41%	-1.36%
Interest Expense	$4.278M	-$38.30M	$1.230M
YoY Change	247.96%	448.08%	-117.6%
% of Operating Profit
Other Income/Expense, Net	$22.34M		-$35.21M
YoY Change	-163.44%
Pretax Income	$19.21M	-$38.62M	-$36.33M
YoY Change	-152.89%	355.23%	328.18%
Income Tax	$0.00		$0.00
% Of Pretax Income	0.0%
Net Earnings	$19.21M	-$38.62M	-$36.33M
YoY Change	-152.89%	355.23%	328.18%
Net Earnings / Revenue	21892.75%	-220685.71%	-22082.21%
Basic Earnings Per Share	$7.37		-$62.69
Diluted Earnings Per Share	$5.61	-$31.93M	-$62.69
COMMON SHARES
Basic Shares Outstanding	2.605M shares		579.5K shares
Diluted Shares Outstanding	3.249M shares

Balance Sheet

Concept	2021	2020 Q4	2020
SHORT-TERM ASSETS
Cash & Short-Term Investments	$10.72M	$98.01K	$98.01K
YoY Change	10841.61%	10.56%	10.56%
Cash & Equivalents		$98.01K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory	$10.87K	$0.00
Prepaid Expenses
Receivables	$2.490K	$0.00	$0.00
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$10.74M	$98.01K	$98.01K
YoY Change	10855.23%	3.99%	3.99%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$3.280K
YoY Change
Total Long-Term Assets	$531.0K	$619.8K	$619.8K
YoY Change	-14.33%	41.97%	41.97%
TOTAL ASSETS
Total Short-Term Assets	$10.74M	$98.01K	$98.01K
Total Long-Term Assets	$531.0K	$619.8K	$619.8K
Total Assets	$11.27M	$717.8K	$717.8K
YoY Change	1469.87%	35.23%	35.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$761.9K	$350.9K	$350.9K
YoY Change	117.12%	9.39%	9.39%
Accrued Expenses	$24.39K	$159.8K	$159.8K
YoY Change	-84.73%	32.6%	32.6%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$788.7K	$788.7K
YoY Change	-100.0%	-25.75%	-25.75%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.050M	$40.52M	$40.52M
YoY Change	-97.41%	371.05%	371.05%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.050M	$40.52M	$40.52M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$1.050M	$40.52M	$40.52M
YoY Change	-97.41%	371.05%	371.05%
SHAREHOLDERS EQUITY
Retained Earnings		-$61.89M
YoY Change
Common Stock		$1.537K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$10.22M	-$39.80M	-$39.80M
YoY Change
Total Liabilities & Shareholders Equity	$11.27M	$717.8K	$717.8K
YoY Change	1469.87%	35.23%	35.23%

Cashflow Statement

Concept	2021	2020 Q4	2020
OPERATING ACTIVITIES
Net Income	$19.21M	-$38.62M	-$36.33M
YoY Change	-152.89%	355.23%	328.18%
Depreciation, Depletion And Amortization	$92.08K	$16.77K	$66.79K
YoY Change	37.86%	51.22%	147.83%
Cash From Operating Activities	-$2.216M	$56.98K	-$434.6K
YoY Change	409.9%	-122.57%	-64.18%
INVESTING ACTIVITIES
Capital Expenditures	$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities		-$250.0K	-$250.0K
YoY Change
Cash From Investing Activities	$0.00	-$250.0K	-$250.0K
YoY Change	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$14.76M		$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$12.84M	252.3K	$693.9K
YoY Change	1750.59%	37.99%	-30.45%
NET CHANGE
Cash From Operating Activities	-$2.216M	56.98K	-$434.6K
Cash From Investing Activities	$0.00	-250.0K	-$250.0K
Cash From Financing Activities	$12.84M	252.3K	$693.9K
Net Change In Cash	$10.63M	59.30K	$9.364K
YoY Change	113375.63%	-185.23%	-104.35%
FREE CASH FLOW
Cash From Operating Activities	-$2.216M	$56.98K	-$434.6K
Capital Expenditures	$0.00
Free Cash Flow	-$2.216M
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	dei	Auditor Firm AuditorFirmId	457
CY2021	us-gaap	Revenues Revenues	87754	USD
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	47949	USD
CY2021	us-gaap	Gross Profit GrossProfit	39805	USD
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	109180	USD
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2964490	USD
CY2021	us-gaap	Operating Expenses OperatingExpenses	3165754	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-3125949	USD
CY2021	us-gaap	Interest Expense InterestExpense	4278433	USD
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6338864	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1537074	shares
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	6339	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	1537	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	53879215	USD
CY2021Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	2485	USD
CY2020Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	0	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	10866	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	0	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	10737221	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	98012	USD
CY2021Q4	us-gaap	Other Assets OtherAssets	3281	USD
CY2020Q4	us-gaap	Other Assets OtherAssets	0	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	527679	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	619763	USD
CY2021Q4	us-gaap	Assets Assets	11268181	USD
CY2020Q4	us-gaap	Assets Assets	717775	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	761862	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	350899	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	24385	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	159771	USD
CY2021Q4	us-gaap	Management Fee Payable ManagementFeePayable	250000	USD
CY2020Q4	us-gaap	Management Fee Payable ManagementFeePayable	468782	USD
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	0	USD
CY2020Q4	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	409649	USD
CY2021Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	0	USD
CY2020Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	788701	USD
CY2021Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	14194	USD
CY2020Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	10800	USD
CY2021Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	0	USD
CY2020Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	38741832	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1050441	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	40520785	USD
CY2021Q4	us-gaap	Preferred Stock No Par Value PreferredStockNoParValue	0.001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	7000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	7000000	shares
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0.001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	25000000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	6000000000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6338872	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1537082	shares
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	22082689	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-43667814	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-61890236	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	10217740	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-39803010	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11268181	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	717775	USD
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	92084	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	66792	USD
CY2021	us-gaap	Derivative Gain On Derivative DerivativeGainOnDerivative	12364084	USD
CY2021	celz	Dividends On Preferred Stock DividendsOnPreferredStock	-27725	USD
CY2021	celz	Cashless Exercise Of Warrants Amount CashlessExerciseOfWarrantsAmount	0	USD
CY2021	celz	Warrants Issued With Notes Payable WarrantsIssuedWithNotesPayable	2097629	USD
CY2020	us-gaap	Interest Expense InterestExpense	1229590	USD
CY2021	celz	Gain On Extinguishment Of Convertible Notes GainOnExtinguishmentOfConvertibleNotes	585601	USD
CY2020	celz	Gain On Extinguishment Of Convertible Notes GainOnExtinguishmentOfConvertibleNotes	0	USD
CY2021	celz	Change In Fair Value Of Derivatives Liabilities ChangeInFairValueOfDerivativesLiabilities	26030549	USD
CY2020	celz	Change In Fair Value Of Derivatives Liabilities ChangeInFairValueOfDerivativesLiabilities	-33980805	USD
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	22337717	USD
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1383332	USD
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-35210395	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	19211768	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-36325230	USD
CY2021	us-gaap	Interest Income Expense After Provision For Loan Loss InterestIncomeExpenseAfterProvisionForLoanLoss	0	USD
CY2020	us-gaap	Interest Income Expense After Provision For Loan Loss InterestIncomeExpenseAfterProvisionForLoanLoss	0	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	19211768	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-36325230	USD
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	7.37
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-62.69
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	5.61
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-62.69
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2605057	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	579461	shares
CY2021	celz	Weighted Average Number Of Shares Outstanding Diluted WeightedAverageNumberOfSharesOutstandingDiluted	3248619	shares
CY2020	celz	Weighted Average Number Of Shares Outstanding Diluted WeightedAverageNumberOfSharesOutstandingDiluted	579461	shares
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-8071499	USD
CY2020	celz	Common Stock Issued For Related Party Management And Patent Liabilities Amount CommonStockIssuedForRelatedPartyManagementAndPatentLiabilitiesAmount	160000	USD
CY2020	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1366705	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	101351	USD
CY2020	us-gaap	Dividends Share Based Compensation DividendsShareBasedCompensation	170323	USD
CY2020	us-gaap	Derivative Gain On Derivative DerivativeGainOnDerivative	2795340	USD
CY2020	celz	Stock Issued During Period Value Reverse Stock Splits StockIssuedDuringPeriodValueReverseStockSplits	0	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-36325230	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-39803010	USD
CY2021	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	462000	USD
CY2021	celz	Common Stock Issued For Related Party Management And Patent Liabilities Amount CommonStockIssuedForRelatedPartyManagementAndPatentLiabilitiesAmount	50000	USD
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	14758488	USD
CY2021	celz	Offering Costs OfferingCosts	-105180	USD
CY2021	celz	Preferred Stock Redemptions Amount PreferredStockRedemptionsAmount	-769026	USD
CY2021	us-gaap	Dividends Share Based Compensation DividendsShareBasedCompensation	595380	USD
CY2021	celz	Stock Issued During Period Value Reverse Stock Splits StockIssuedDuringPeriodValueReverseStockSplits	0	USD
CY2021	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	0	USD
CY2021	us-gaap	Profit Loss ProfitLoss	19211768	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	10217740	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	19211768	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-36325230	USD
CY2021	us-gaap	Dividends Share Based Compensation DividendsShareBasedCompensation	595380	USD
CY2020	us-gaap	Dividends Share Based Compensation DividendsShareBasedCompensation	170323	USD
CY2020	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-33980805	USD
CY2021	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	93821	USD
CY2020	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	0	USD
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	585601	USD
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	92084	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	66792	USD
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	4157850	USD
CY2020	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	979960	USD
CY2021	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	26030549	USD
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2485	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	5600	USD
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-10866	USD
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	410963	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	30114	USD
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	20635	USD
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	167029	USD
CY2021	us-gaap	Increase Decrease In Payables To Customers IncreaseDecreaseInPayablesToCustomers	168782	USD
CY2020	us-gaap	Increase Decrease In Payables To Customers IncreaseDecreaseInPayablesToCustomers	-490051	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2215782	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-434556	USD
CY2021	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	0	USD
CY2020	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	250000	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-250000	USD
CY2021	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	3887750	USD
CY2020	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
CY2021	celz	Payments On Notes Payable PaymentsOnNotesPayable	-5251176	USD
CY2020	celz	Payments On Notes Payable PaymentsOnNotesPayable	0	USD
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	3281	USD
CY2020	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2021	celz	Payments On Convertible Notes Payable PaymentsOnConvertibleNotesPayable	0	USD
CY2020	celz	Payments On Convertible Notes Payable PaymentsOnConvertibleNotesPayable	-17000	USD
CY2021	celz	Proceeds From Convertible Notes Payable ProceedsFromConvertibleNotesPayable	435040	USD
CY2020	celz	Proceeds From Convertible Notes Payable ProceedsFromConvertibleNotesPayable	710920	USD
CY2021	celz	Proceeds From Issuance Of Preferred Stock ProceedsFromIssuanceOfPreferredStock	462000	USD
CY2020	celz	Proceeds From Issuance Of Preferred Stock ProceedsFromIssuanceOfPreferredStock	0	USD
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	14758488	USD
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2021	celz	Payment Of Offering Costs PaymentOfOfferingCosts	-105180	USD
CY2020	celz	Payment Of Offering Costs PaymentOfOfferingCosts	0	USD
CY2021	us-gaap	Preferred Stock Redemption Premium PreferredStockRedemptionPremium	196751	USD
CY2020	us-gaap	Preferred Stock Redemption Premium PreferredStockRedemptionPremium	0	USD
CY2021	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	223394	USD
CY2020	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	0	USD
CY2021	us-gaap	Increase Decrease In Due To Other Related Parties IncreaseDecreaseInDueToOtherRelatedParties	-220000	USD
CY2020	us-gaap	Increase Decrease In Due To Other Related Parties IncreaseDecreaseInDueToOtherRelatedParties	0	USD
CY2021	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	705405	USD
CY2020	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	12841640	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	693920	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	10625858	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	9364	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	98012	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	88648	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10723870	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	98012	USD
CY2021	us-gaap	Interest Paid Net InterestPaidNet	9186	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	6000	USD
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	USD
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	USD
CY2021	celz	Accrued Dividends On Preferred Stock AccruedDividendsOnPreferredStock	27725	USD
CY2020	celz	Accrued Dividends On Preferred Stock AccruedDividendsOnPreferredStock	0	USD
CY2021	celz	Warrants Issued With Notes Payable And As A Service Fee WarrantsIssuedWithNotesPayableAndAsAServiceFee	2097629	USD
CY2020	celz	Warrants Issued With Notes Payable And As A Service Fee WarrantsIssuedWithNotesPayableAndAsAServiceFee	0	USD
CY2021	celz	Conversion Of Notes Payable Accrued Interest And Derivative Liabilities Into Common Stock ConversionOfNotesPayableAccruedInterestAndDerivativeLiabilitiesIntoCommonStock	13747415	USD
CY2020	celz	Conversion Of Notes Payable Accrued Interest And Derivative Liabilities Into Common Stock ConversionOfNotesPayableAccruedInterestAndDerivativeLiabilitiesIntoCommonStock	4162045	USD
CY2021	celz	Debt Conversion Converted Instrument Conversion Of Management Fees And Patent Liability DebtConversionConvertedInstrumentConversionOfManagementFeesAndPatentLiability	50000	USD
CY2020	celz	Debt Conversion Converted Instrument Conversion Of Management Fees And Patent Liability DebtConversionConvertedInstrumentConversionOfManagementFeesAndPatentLiability	160000	USD
CY2021	celz	Discounts On Convertible Notes Payable Due To Derivative Liabilities DiscountsOnConvertibleNotesPayableDueToDerivativeLiabilities	134640	USD
CY2020	celz	Discounts On Convertible Notes Payable Due To Derivative Liabilities DiscountsOnConvertibleNotesPayableDueToDerivativeLiabilities	0	USD
CY2021	celz	Exchange Of Preferred Stock For Notes Payable ExchangeOfPreferredStockForNotesPayable	572275	USD
CY2020	celz	Exchange Of Preferred Stock For Notes Payable ExchangeOfPreferredStockForNotesPayable	0	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	0	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	101351	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	989346	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	0	USD
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Use of Estimates</strong></em> - The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2021Q4	us-gaap	Time Deposits At Or Above Fdic Insurance Limit TimeDepositsAtOrAboveFDICInsuranceLimit	250000	USD
CY2021Q3	celz	Obligation Of The Initial Payment ObligationOfTheInitialPayment	300000	USD
CY2020Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	38741832	USD
CY2021	celz	Addition Of New Conversion Option Derivatives AdditionOfNewConversionOptionDerivatives	1077757	USD
CY2021	celz	Extinguishmentmodification Extinguishmentmodification	-727344	USD
CY2021	celz	Conversion Of Note Derivatives ConversionOfNoteDerivatives	-12364084	USD
CY2021	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-26728161	USD
CY2021Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	0	USD
CY2021Q3	celz	Common Stock Issue CommonStockIssue	84656	USD
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	109180	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	0	USD
CY2021Q1	celz	Number Of Share Issuance Of Common Stock To Jadi Cell NumberOfShareIssuanceOfCommonStockToJadiCell	180180	shares
CY2021	celz	Summary Of Outstanding Securities SummaryOfOutstandingSecurities	<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>For the Year Ended December 31, 2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Weighted average common shares outstanding used in calculating basic earnings per share</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,605,057</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Effect of Series B and C preferred stock</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Effect of warrants and options</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">643,562</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Effect of convertible notes payable</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Effect of convertible related party management fee and patent liabilities</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Weighted average common shares outstanding used in calculating diluted earnings per share</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 2pt double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">3,248,619</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Net income as reported</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">19,211,768</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Add - Interest on convertible notes payable</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Subtract deemed dividend on warrant reset</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 3px double;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">(989,346</p></td><td style="PADDING-BOTTOM: 3px;"><p style="font-size:10pt;font-family:times new roman;margin:0px">)</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net income available to common stockholders</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">18,222,422</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Diluted income per Share</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 2pt double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 2pt double;width:9%;vertical-align:bottom;text-align:right;">5.61</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Interest on non-convertible notes</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,151</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2605057	shares
CY2021	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	643562	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3248619	shares
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	19211768	USD
CY2021	celz	Subtract Deemed Dividend On Warrant Reset SubtractDeemedDividendOnWarrantReset	-989346	USD
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	18222422	USD
CY2021	us-gaap	Diluted Earnings Per Share Pro Forma DilutedEarningsPerShareProForma	5.61
CY2021	celz	Interest On Nonconvertible Notes InterestOnNonconvertibleNotes	1151	USD
CY2016Q1	celz	No Of Share Exchange NoOfShareExchange	431111	shares
CY2016Q1	celz	Restricted Common Stock RestrictedCommonStock	100000	USD
CY2017Q2	celz	Payments Upon Completion Of Irb Clinical Trial PaymentsUponCompletionOfIrbClinicalTrial	200000	USD
CY2017Q2	celz	Payments In The Event Of Commercialization Of Technology PaymentsInTheEventOfCommercializationOfTechnology	300000	USD
CY2020Q4	celz	Common Stock Issue CommonStockIssue	6667	USD
CY2020Q4	celz	Company Paid CompanyPaid	50000	USD
CY2020Q4	celz	Obligation Of The Initial Payment ObligationOfTheInitialPayment	300000	USD
CY2020Q4	celz	Common Stock Issue CommonStockIssue	133	USD
CY2021Q3	celz	Company Paid CompanyPaid	40000	USD
CY2021Q1	celz	Company Paid CompanyPaid	50000	USD
CY2021Q1	celz	Obligation Of The Initial Payment ObligationOfTheInitialPayment	300000	USD
CY2021Q1	celz	Common Stock Issue CommonStockIssue	89286	USD
CY2021Q4	celz	Obligation Of The Initial Payment ObligationOfTheInitialPayment	300000	USD
CY2020Q4	celz	License Agreement Description LicenseAgreementDescription	(the “Upfront Royalty”), which can also be paid in CELZ stock at a discount of 25% of the closing price of $0.0037, which is based on the date of this agreement
CY2021	celz	Continuing Royalty Description ContinuingRoyaltyDescription	Within thirty (30) days of the end of each calendar quarter during the term of this Agreement, Licensee will pay Licensor five percent (5%) of the Net Income of ImmCelz™
CY2020Q4	celz	License Fees LicenseFees	250000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Two FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo	92085	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Three FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree	92085	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Four FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour	92085	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	91084	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	60388	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	100000	USD
CY2021Q4	celz	Total Future Amortization Cost TotalFutureAmortizationCost	527677	USD
CY2020Q4	celz	Licensing Agreements Beginning Balance LicensingAgreementsBeginningBalance	760000	USD
CY2020Q4	celz	Accumulated Amortization Beginning Balance AccumulatedAmortizationBeginningBalance	-140237	USD
CY2021	celz	Accumulated Amortization Addition Of New Assets AccumulatedAmortizationAdditionOfNewAssets	0	USD
CY2021	us-gaap	Adjustment For Amortization AdjustmentForAmortization	0	USD
CY2021	celz	Accumulated Amortization AccumulatedAmortization	-92084	USD
CY2021Q4	celz	Licensing Agreementsendingbalance LicensingAgreementsendingbalance	760000	USD
CY2021Q4	celz	Accumulated Amortization Ending Balance AccumulatedAmortizationEndingBalance	-232321	USD
CY2018Q1	celz	Series A Preferred Stock Shares Issued SeriesAPreferredStockSharesIssued	3000000	shares
CY2018Q1	celz	Cancellation Of Debt CancellationOfDebt	150000	USD
CY2018Q1	celz	Series A Preferred Stock Description Of Surrender And Exchange SeriesAPreferredStockDescriptionOfSurrenderAndExchange	Mr. Warbington surrendered the Series A Preferred Stock to the Company in December 2021 immediately prior to the closing of the Company’s public offering in exchange for $150,000 plus 8% interest on such amount from January 2018 until the date of surrender
CY2020Q4	celz	Agreement Description AgreementDescription	Company entered into a patent license agreement with Jadi Cell, LLC, a company owned and controlled by Dr. Amit Patel, a former director of the Company
CY2021Q2	celz	Proceeds From Chairman ProceedsFromChairman	50000	USD
CY2021Q2	celz	Proceeds From Director ProceedsFromDirector	150000	USD
CY2021Q2	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.05	pure
CY2021Q3	celz	Original Sale Discount Percentage OriginalSaleDiscountPercentage	0.15	pure
CY2021Q3	us-gaap	Debt Instrument Periodic Payment Principal DebtInstrumentPeriodicPaymentPrincipal	4456176	USD
CY2021	celz	Amortization To Interest Expense AmortizationToInterestExpense	3299000	USD
CY2021	celz	Debt Conversion Shares Issued DebtConversionSharesIssued	789727	shares
CY2021	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	1383332	USD
CY2021	celz	Debt Conversion Converrted Instrument Shares Issued DebtConversionConverrtedInstrumentSharesIssued	37870	shares
CY2021	celz	Common Stock Issued For Cashless Warrant Exercise Shares CommonStockIssuedForCashlessWarrantExerciseShares	43167	shares
CY2020	celz	Description Of Trading Days DescriptionOfTradingDays	the lowest trade price during the previous 20 trading days, or the volume weighted average price over the prior 15 trading days
CY2020	celz	Debt Conversion Shares Issued DebtConversionSharesIssued	1363463	shares
CY2020	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	1366705	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.202	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.022	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.009	pure
CY2021	us-gaap	Provision For Other Losses ProvisionForOtherLosses	0	USD
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	8300000	USD
CY2021	celz	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rates EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRates	0.21	pure
CY2020	celz	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rates EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRates	0.089	pure
CY2021Q4	celz	Initial Derivative Liabilities InitialDerivativeLiabilities	1077757	USD
CY2021	celz	Fair Value Assumption Expected Terms FairValueAssumptionExpectedTerms	P1Y
CY2021Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	697602	USD
CY2021Q1	celz	Gain Loss Related To Change In Fair Market Value Of Derivative Liabilities GainLossRelatedToChangeInFairMarketValueOfDerivativeLiabilities	28476039	USD
CY2021Q3	us-gaap	Workers Compensation Discount Percent WorkersCompensationDiscountPercent	0.15	pure
CY2021Q3	srt	Mortgage Loans On Real Estate Principal Amount Of Delinquent Loans MortgageLoansOnRealEstatePrincipalAmountOfDelinquentLoans	4456176	USD
CY2020Q4	celz	Initial Derivative Liabilities InitialDerivativeLiabilities	2572723	USD
CY2020	celz	Fair Value Assumption Expected Terms FairValueAssumptionExpectedTerms	P1Y
CY2020Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	1864233	USD
CY2020	celz	Gain Loss Related To Change In Fair Market Value Of Derivative Liabilities GainLossRelatedToChangeInFairMarketValueOfDerivativeLiabilities	-33980805	USD
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	35670	USD
CY2020	celz	Warrant Descriptions WarrantDescriptions	we granted a total of 60,000 warrants to three of our board members at that time, Dr. Ichim, Dr. Patel, and Donald Dickerson (Mr. Dickerson remains a board member) at an exercise price of $2.00.
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	102081	USD
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P3Y
CY2021	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	325596	USD
CY2020	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	250771	USD
CY2021	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	9460	USD
CY2020	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	69671	USD
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	416056	USD
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	320442	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	2097315	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	1593282	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	67086	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	155063	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2164401	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1748345	USD
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.002	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.002	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.000	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.000	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.238	pure
CY2019Q2	us-gaap	Loss Contingency Damages Awarded Value LossContingencyDamagesAwardedValue	600749	USD
CY2021Q4	us-gaap	Product Liability Contingency Accrual Present Value ProductLiabilityContingencyAccrualPresentValue	707116	USD
CY2022Q1	us-gaap	Deferred Compensation Arrangement With Individual Cash Awards Granted Percentage DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage	0.30	pure

Files In Submission

Name	View Source	Status
0001477932-22-001741-index-headers.html	Edgar Link	pending
0001477932-22-001741-index.html	Edgar Link	pending
0001477932-22-001741.txt	Edgar Link	pending
0001477932-22-001741-xbrl.zip	Edgar Link	pending
celz-20211231.xsd	Edgar Link	pending
celz-20211231_cal.xml	Edgar Link	unprocessable
celz-20211231_def.xml	Edgar Link	unprocessable
celz-20211231_lab.xml	Edgar Link	unprocessable
celz-20211231_pre.xml	Edgar Link	unprocessable
celz_10k.htm	Edgar Link	pending
celz_10kimg5.jpg	Edgar Link	pending
celz_10kimg6.jpg	Edgar Link	pending
celz_10kimg7.jpg	Edgar Link	pending
celz_10k_htm.xml	Edgar Link	completed
celz_ex311.htm	Edgar Link	pending
celz_ex312.htm	Edgar Link	pending
celz_ex321.htm	Edgar Link	pending
celz_ex322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CELZ
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. Stock $celz

2021 Form 10-K Financial Statement

#000147793222001741 Filed on March 30, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CELZ CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. Stock $celz

2021 Form 10-K Financial Statement

#000147793222001741 Filed on March 30, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CELZ
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. Stock $celz